Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EpimAb Biotherapeutics Inc.

www.epimab.com

Latest From EpimAb Biotherapeutics Inc.

Venture Funding Deals: Locana Gets Ready To Take On ALS, Huntington's With Gene Editing

The series A fundraising will help Locana bring CRISPR gene editing to diseases with dysfunctional RNA. Artizan and OncoMyx are among the other firms with recent series A rounds.

 

Deals Financing

Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.

Financing StartUps and SMEs

Bispecific Antibodies: US FDA May Require Comparison To Approved Monospecific Product

When approved therapies target the same antigens as the investigational bispecific antibody, FDA may request a comparative clinical trial, draft guidance notes.

Guidance Documents Biologics

China's EpimAb Advances Bispecific Antibody To Rival Janssen Candidate

EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule EMB01, an EGFR-cMET bispecific antibody.

StartUps and SMEs Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • EpimAb Biotherapeutics Inc.
  • Senior Management
  • Chengbin Wu, PhD, CEO
    Stephan Lensky, PhD, CBO
    Bin Peng, MD, PhD, CMO
  • Contact Info
  • EpimAb Biotherapeutics Inc.
    Phone: 21 61951000
    6th Fl., Bldg. 2, Jinchuang Bldg
    4560 Jinke Rd.
    Shanghai, 201204
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register